Peter Krein

Peter Krein currently serves as the VP of Diagnostic Development at Eli Lilly and Company, focusing on the development of diagnostics for personalized care related to investigational and regulated medicines. Previously, Peter held the position of Senior Vice President of Precision Medicine at Boundless Bio, where responsibilities included developing novel ecDNA biomarker clinical trial assays and potential companion diagnostics. Before that, Peter served as Executive Director of Clinical Biomarkers, Diagnostic Development, and Dx Medical at Loxo Oncology, where diagnostic strategies for pipeline candidates were formulated. Peter’s career also includes a role as Managing Director at Diaceutics, providing consulting services on diagnostic partnerships and commercialization strategies, as well as Senior Director of Medical Affairs Development at QIAGEN, leading clinical evidence plans for market access. Educational qualifications include a fellowship in Functional Genomics and Molecular Immunology from the University of Arizona College of Medicine and two Ph.D. degrees in Medical Science from the University of Calgary.